KRAS and cholangiocarcinoma: Cetuximab did not inhibit cell growth in CC cells carrying a heterozygous Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation, but had a dose-dependent effect on growth of CC cells displaying the KRAS wild-type [236].